Six questions about ASC implant billing, answered

Ask any of these six questions out loud in an ASC and you will get a confident answer. Ask the regulation, the contract and the biller working the denials, and you can get three different ones.

That is not carelessness. Implant billing sits on a fault line. On one side is federal regulation, which is specific, public and checkable. On the other are commercial contracts, which are none of those things. “Are implants billed separately in an ASC?” has a firm answer for Medicare and no general answer at all for a commercial payer, and both halves circulate online as though they were the same kind of fact.

So these questions look like they should resolve cleanly, and mostly they do not. A couple have a flat regulatory answer that the industry widely gets wrong. The rest have no single answer, only a contract. That gap is where implant revenue disappears: an undefined term, an unchecked threshold, an invoice that never got attached.

Here is what is actually known on each, and what is not.

Medicare has a firm answer. Commercial payers each have their own.

Are implants billed separately in an ASC? For Medicare the answer is settled, and it is no, with one narrow exception.

CMS states it directly in Chapter 14 of the Medicare Claims Processing Manual: an ASC may not bill separately for implantable devices that lack OPPS pass-through status, and payment for implantable prosthetic devices without pass-through status is included in the ASC payment for the covered surgical procedure. A separately billed non-pass-through implant comes back denied with CARC 97, RARC M97 and MSN 16.32.

The exception is pass-through devices, which carry payment indicator J7. Those are contractor-priced based on acquisition cost or invoice, and they are the implants an ASC does bill separately to Medicare.

One correction worth making, because it is everywhere. The denial code for a separately billed non-pass-through implant is widely published as CARC 96. It is wrong. CARC 96 applies to a different situation entirely, one involving payment indicators E5 and Y5. If you are building a denial playbook off an article that says 96, you are mapping the wrong root cause to the wrong fix.

Commercial payers are a different question, and there is no single answer to give. Becker's, reporting a study by Advantien (an ASC supply purchasing company, so treat this as vendor-sourced), describes four models in use: no separate implant reimbursement at all; reimbursement at 100% of implant cost plus a markup; reimbursement only on implants above a dollar threshold; and carve-outs negotiated for specific implants. Four models in circulation means the answer at the center down the road tells you nothing about yours.

The two halves of this question are not the same kind of fact. The Medicare answer is fixed by regulation, and the commercial answer is whatever your contract says it is. Only one of them can be looked up.

This is also why Bill-Back does not work Medicare implant claims. CMS bundles the implant into the procedure payment, so there is nothing separate to recover there. The implant money that goes uncollected sits on the commercial side, which is exactly where the rules stop being public.

“Implant” is not a defined term, which is why the argument never ends

What counts as an implant versus a supply? There is no single regulatory definition to appeal to, and that absence is the whole problem.

Medicare's packaging language covers implanted prosthetic devices and implanted DME. It does not draw the boundary against consumable surgical supplies, which appear as their own separately listed category and are also packaged into the procedure payment. For Medicare the distinction rarely bites, since both end up bundled either way. For a commercial contract with an implant carve-out, that same distinction decides whether a line gets paid.

Billers describe the fight in concrete terms. On AAPC's forums they report payers denying K-wires, screws and pins as supplies while their own clinical leadership classifies the same items as implants. Read that as reported practitioner experience rather than as a rule: it tells you the argument is common, not how it resolves.

What can be said flatly is the structural part. When a contract does not define the word, the payer's definition wins by default. Not because the payer is right, but because the party holding the written definition is the party that gets to apply it.

A carve-out is only as good as the definition of “invoice cost”

What is an implant carve-out, and what counts as “invoice cost”? The first half is well understood. A carve-out is a negotiated provision that reimburses high-cost implants separately from the case rate, typically at invoice cost plus a percentage, above a dollar threshold. That description is vendor-sourced: it comes from Becker's, reporting the Advantien study.

The second half is where the money is, and in commercial contracts it is frequently left blank. Contracts often do not define “invoice cost” at all, which quietly hands the interpretation to the payer.

Where regulators have had to define it, they are precise about it.

The Department of Labor's OWCP fee schedule sets acquisition cost as wholesale cost plus shipping, handling and sales tax, net of all discounts, billed together as a single charge.

Illinois's workers' compensation fee schedule reaches the same variables by a different route: reimbursement at 25% above the net manufacturer's invoice price less rebates, plus actual reasonable and customary shipping charges.

Put them side by side and three variables decide the number in both: shipping, tax and rebates. Neither regulator was willing to leave any of the three to interpretation, because each one moves the payable amount, and they do not all move it in the same direction. A commercial contract that is silent on all three has already conceded the argument.

Note what these two definitions are not. They are not an industry standard, and neither one binds a commercial payer. They are useful because they show what a carefully drafted definition looks like: three variables, each named, each resolved. A contract that says “invoice cost” and stops has not defined anything.

Which makes the questions worth putting in writing narrow and answerable. Does invoice cost include freight. Does it include sales tax. Is it gross or net of rebates and discounts. And what document does the payer accept as proof of it.

The audit is usually lost on the paperwork, not the code

What documentation does an ASC actually need to get paid? The most useful answer is not a checklist. It is CMS's own audit data on why ASC payments go wrong.

Where those improper payments came from is the part worth pinning to the wall.

• Insufficient documentation58.8%
• No documentation34%
• Incorrect coding7.2%

CMS Medicare Learning Network, Medicare Provider Compliance Tips for Ambulatory Surgical Centers, 2024 reporting period.

Documentation failures outweigh coding failures by about thirteen to one. The claim is rarely lost on the code. It is lost on what was not attached to it.

That is the only independent statistic in this series, and it is worth saying why that matters. Nearly everything published about implant reimbursement comes from companies that sell implant reimbursement services, this site included. This number does not. It is produced by the agency doing the paying, about its own claims.

On invoices specifically, commercial requirements are contract-dependent and you will have to read yours. OWCP is concrete: wholesale invoices retained for a minimum of three years, a hard copy submitted whenever an individual device or supply costs $150 or more, or on request, and payment may be delayed without it.

Treat the invoice as part of the submission rather than as backup you produce when someone asks.

Denied claims get worked. Underpaid ones look like wins.

What do you do when an implant claim is denied or underpaid? Start from the exact CARC and RARC on the remittance, because the code identifies the root cause and the root cause determines the fix. Working off the general category rather than the specific code is how the same claim gets resubmitted unchanged.

From there the sequence is unglamorous:

• Attach the invoice and the operative note. The invoice establishes cost; the operative note establishes that the device was implanted in that case.
• Cite the specific contract provision that entitles the center to payment. Becker's guidance on implant reimbursement stresses appealing denials and underpayments on contract grounds rather than on general appeal language.
• File inside the payer's window. That window varies by payer and by contract, and any single number of days you read online is somebody's contract, not necessarily yours. Look it up in your agreement rather than in an article.

Becker's also warns that recovery odds fall sharply once you are past the initial claims cycle. Time is the variable a center controls least well and pays for most.

Then there is the part that is structurally easy to miss. Denials are visible by design. They land in a work queue, they show up on a denial report, and clearing them is somebody's number. None of that happens for an implant line that paid, just below what the contract entitles the center to. A claim that paid, just not fully, reads as a success in every report built to surface problems.

Underpaid implant lines sitting inside otherwise-paid claims are the ones least likely to get worked. Not because anyone is ignoring them, but because nothing in the workflow raises a hand about them.

Implant charge capture is shared, and shared is not the same as owned

So who actually owns implant charge capture? On paper it is shared between materials and billing. In practice, a step that is shared and that neither team is measured on is a step that tends not to happen on schedule.

Two vendor sources describe the same shape, and both deserve that label out loud.

in2itive, an RCM firm, prescribes the fix in some detail: the materials manager coordinating with billing on cost and verification questions, all invoices made available during the RCM process, and invoices matched against the implant log as a checks-and-balance. A process document gets written for the step that is not happening reliably, not for the one that is.

Advantien, separately, lists “no watchdog to ensure payer contracts are honored” among the most common implant reimbursement failures. Also vendor-sourced, also a company positioned to be that watchdog.

So is Bill-Back. Both of those sources describe a gap they sell the fix for, and you are reading this on the blog of a company built to fill the same gap. Weigh it accordingly. The reason to take the argument seriously is not that three vendors agree on it. It is that CMS's audit data, which sells nothing, says the dominant failure mode in ASC payment is documentation rather than coding, and an invoiced implant that never reached a claim is the most complete documentation failure available.

None of that requires anyone to have done their job badly. Both roles are performed correctly, and the step that would compare them is not what either role is measured on.

Bill-Back is early. There are no customer logos on this site and we are not going to invent any, so here is the mechanism instead. We read two files a center already has: the monthly case log export from the PMS, and the vendor invoice PDFs. Structured patient identifiers are stripped in your browser before anything uploads; clinical free text can still carry an incidental identifier, so everything we receive is handled under a signed BAA. Supply notes are matched to vendor catalog numbers and priced at your contracted rate. Then someone on your side clears anything already on a claim, which is the step that separates matched value from recoverable dollars. What survives becomes a payer-ready Recoup Packet: the matched invoice line, the contract math and an appeal letter, submitted by your own biller.

Commercial payers only, for the reason in section one. Free to audit, and if it finds nothing you owe nothing.

You can estimate what that seam is worth at your case volume in about thirty seconds, or start a free audit against a month of your own files.

Sources

Every figure above traces to one of these. They were read in full rather than pulled from search results.

Government and regulatory

• Medicare Claims Processing Manual, Chapter 14: Ambulatory Surgical Centers, CMS (Rev. 13836, June 2026). Sections 10.2, 10.4, 40 and 60.2.
• Payment Policy for Ambulatory Surgery Center Services, OWCP Medical Fee Schedule, U.S. Department of Labor.
• Ill. Admin. Code tit. 50, section 9110.90, Illinois Workers' Compensation Commission Medical Fee Schedule, via Cornell LII.
• Medicare Provider Compliance Tips: Ambulatory Surgical Centers, CMS Medicare Learning Network.

Trade press

• "8 guidelines to improve ASC implant reimbursement", Becker's ASC Review, 2018.

Vendor-sourced, flagged in-line wherever cited above

• "The burden of implant costs: 10 things ASCs need to know", Becker's ASC Review, February 12 2025, reporting a July 2024 study by Advantien.
• "Mastering Proper Implant Charges & ASC Billing Processes", in2itive Business Solutions.

Practitioner forum, reported experience rather than rule

• AAPC discussion, "Implant billing".